SCHEMBL2177914

SCHEMBL2177914

CC(C)C(C(=O)O)N1Cc2ccc(-c3ccc(NC(=O)Nc4ccc(F)c(F)c4)cn3)cc2C1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 7/20 0.44
CSGALNACT1 Q8TDX6 1/20 0.41
LMNA P02545 2/20 0.39
THRB P10828 1/20 0.39
EGFR P00533 1/20 0.38
PDGFRB P09619 1/20 0.38
KIT P10721 1/20 0.38
FGFR1 P11362 1/20 0.38
FLT1 P17948 1/20 0.38
KDR P35968 1/20 0.38
EPHB4 P54760 1/20 0.38
TEK Q02763 1/20 0.38
MAPT P10636 1/20 0.38
SDCBP O00560 2/20 0.38
SDC2 P34741 2/20 0.38
KCNJ6 P48051 1/20 0.37
KCNJ5 P48544 1/20 0.37
KCNJ3 P48549 1/20 0.37
VHL P40337 2/20 0.37
HTR2A P28223 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13718763 1.00 DGAT1 (0.44) DGAT1CSGALNACT1LMNATHRBEGFR
SCHEMBL2224009 0.92 HTR2A (0.40) DGAT1CSGALNACT1LMNATHRBEGFR
SCHEMBL2180394 0.92 HTR2A (0.40) DGAT1CSGALNACT1LMNATHRBEGFR
SCHEMBL2176926 0.89 DGAT1 (0.43) DGAT1CSGALNACT1LMNATHRBKIT
SCHEMBL13718779 0.89 DGAT1 (0.43) DGAT1CSGALNACT1LMNATHRBKIT
SCHEMBL2179349 0.89 CSGALNACT1 (0.43) DGAT1CSGALNACT1LMNATHRBEGFR
SCHEMBL2176967 0.89 CSGALNACT1 (0.43) DGAT1CSGALNACT1LMNATHRBEGFR
SCHEMBL2177496 0.88 KDR (0.42) DGAT1LMNAKDR
SCHEMBL2364244 0.88 KDR (0.42) DGAT1LMNAKDR
SCHEMBL2179818 0.85 LMNA (0.44) DGAT1CSGALNACT1LMNATHRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US claimed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US claimed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP claimed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO claimed
US-8748426-B2 Inhibitors of diacylglycerol acyl transferase Piramal Enterprises Limited (IN) 2014-06-10 US disclosed
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Enterprises Limited (IN) 2012-11-15 US disclosed
EP-2519500-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE Piramal Healthcare Ltd. (IN) 2012-11-07 EP disclosed
WO-2011080718-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120289505-A1 INHIBITORS OF DIACYLGLYCEROL ACYL TRANSFERASE DGAT1, DGAT2, LCAT DGAT1 1/4885CSGALNACT1 783/4885LMNA 2193/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.